CSL will begin immediate development of an anti-SARS-CoV-2 plasma product with the potential to treat people with serious complications of COVID-19, particularly those whose illness is progressing towards the need for ventilation. The investigational product, COVID-19 Immunoglobulin, will be developed using donations of plasma collected by Australian Red Cross Lifeblood from people who have recovered from COVID-19. This briefing will provide journalists with the opportunity to ask health experts about the treatment ahead of a media conference with The Hon. Greg Hunt at 11.00am (AEST).
Organisation/s: CSL Ltd, Australian Red Cross Lifeblood
Funder: CSL Limited
Media Briefing/Press Conference
Speakers:- Dr Charmaine Gittleson, Chief Medical Officer, CSL Limited
- Dr James Daly, Medical Director, Lifeblood Pathology Services
Press conference recording at title link to this post
No comments:
Post a Comment